Ross University School of Veterinary Medicine Partners With MANRRS to Increase Diversity in Veterinary Profession

Pet owners represent a much more diverse population than the veterinary professionals who care for them and their animals, a gap the American Veterinary Medicine Association (AVMA)1 and the Association of American Veterinary Colleges (AAVMC) 2 are working hard to fill. Ross University School of Veterinary Medicine (RUSVM) is committed to being part of the solution and is proud to announce a new partnership with Minorities in Agriculture, Natural Resources and Related Sciences (MANRRS). This collaboration will further RUSVM’s long-term commitment to increase diversity in the veterinary profession and strengthen the pipeline of highly qualified, diverse students pursuing an education in veterinary medicine.

The partnership will introduce RUSVM to MANRRS chapters across the U.S. with MANRRS members gaining access to exclusive webinars and virtual workshops from RUSVM to increase exposure to the profession. Additionally, qualified students may apply for a newly launched MANRRS scholarship. The partnership will also help establish a professional chapter of MANRRS at RUSVM that will create mentoring opportunities for current RUSVM students and enhanced networking opportunities. To learn more about this partnership, click here.

“It is vitally important that the field of veterinary medicine is representative of the communities that we serve, and Ross University School of Veterinary Medicine is thrilled to take this important step toward increasing diversity in the field,” said Sean Callanan, MVB, CERTVR, MRCVS, PHD, FRCPATH, DIPLECVP, dean of Ross University School of Veterinary Medicine. “As one of the most ethnically diverse AVMA-accredited veterinary schools, the partnership with MANRRS will provide new opportunities for prospective, current and former students, and pave the way for a more diverse workforce.”

According to an American Veterinary Medicine Association (AVMA) report, more than one-third of African Americans surveyed own a pet. However, the vast majority of practicing veterinarians in the U.S. are white3, highlighting a disparity in the diversity of the profession and the people that they serve.

“While facing the dismal reality that more than 85% of Veterinarians are white, MANRRS is committed to partnering with RUSVM to provide underrepresented students access to pursue a career in veterinary medicine,” said Ebony Webber, chief operating officer for MANRRS. “Provided that MANRRS is one of the only and largest organizations focused on diverse talent in agriculture, our student and professional members expect MANRRS to advocate for diversity, equity, and inclusion in areas where minorities are needed to help solve the world’s biggest challenges relating to animal health.”

RUSVM, supported by its parent company, Adtalem Global Education, is committed to cultivating a culture of diversity and inclusivity and creating a diverse global workforce that reflects that culture. To learn more about Adtalem’s commitment to diversity and inclusion, click here.

About Ross University School of Veterinary Medicine

Ross University School of Veterinary Medicine (RUSVM) is an institution of Adtalem Global Education (NYSE:ATGE, member S&amp, P MidCap 400 Index)). Founded in 1982, RUSVM is committed to preparing students to become members and leaders of the worldwide public and professional healthcare team and to advance human, animal and

Read more

Ross University School of Veterinary Medicine Partners With MANRRS to Increase Diversity in Veterinary Profession – Press Release

BASSETERRE, St. Kitts–(Business Wire)–Pet owners represent a much more diverse population than the veterinary professionals who care for them and their animals, a gap the American Veterinary Medicine Association (AVMA)1 and the Association of American Veterinary Colleges (AAVMC) 2 are working hard to fill. Ross University School of Veterinary Medicine (RUSVM) is committed to being part of the solution and is proud to announce a new partnership with Minorities in Agriculture, Natural Resources and Related Sciences (MANRRS). This collaboration will further RUSVM’s long-term commitment to increase diversity in the veterinary profession and strengthen the pipeline of highly qualified, diverse students pursuing an education in veterinary medicine.

The partnership will introduce RUSVM to MANRRS chapters across the U.S. with MANRRS members gaining access to exclusive webinars and virtual workshops from RUSVM to increase exposure to the profession. Additionally, qualified students may apply for a newly launched MANRRS scholarship. The partnership will also help establish a professional chapter of MANRRS at RUSVM that will create mentoring opportunities for current RUSVM students and enhanced networking opportunities. To learn more about this partnership, click here.

“It is vitally important that the field of veterinary medicine is representative of the communities that we serve, and Ross University School of Veterinary Medicine is thrilled to take this important step toward increasing diversity in the field,” said Sean Callanan, MVB, CERTVR, MRCVS, PHD, FRCPATH, DIPLECVP, dean of Ross University School of Veterinary Medicine. “As one of the most ethnically diverse AVMA-accredited veterinary schools, the partnership with MANRRS will provide new opportunities for prospective, current and former students, and pave the way for a more diverse workforce.”

According to an American Veterinary Medicine Association (AVMA) report, more than one-third of African Americans surveyed own a pet. However, the vast majority of practicing veterinarians in the U.S. are white3, highlighting a disparity in the diversity of the profession and the people that they serve.

“While facing the dismal reality that more than 85% of Veterinarians are white, MANRRS is committed to partnering with RUSVM to provide underrepresented students access to pursue a career in veterinary medicine,” said Ebony Webber, chief operating officer for MANRRS. “Provided that MANRRS is one of the only and largest organizations focused on diverse talent in agriculture, our student and professional members expect MANRRS to advocate for diversity, equity, and inclusion in areas where minorities are needed to help solve the world’s biggest challenges relating to animal health.”

RUSVM, supported by its parent company, Adtalem Global Education, is committed to cultivating a culture of diversity and inclusivity and creating a diverse global workforce that reflects that culture. To learn more about Adtalem’s commitment to diversity and inclusion, click here.

About Ross University School of Veterinary Medicine

Ross University School of Veterinary Medicine (RUSVM) is an institution of Adtalem Global Education (NYSE: ATGE; member S&P MidCap 400 Index). Founded in 1982, RUSVM is committed to preparing students to become members and leaders of the worldwide public and professional healthcare team and to advance

Read more

Hygea Precision Medicine Partners With 1health.io to Provide COVID-19 Saliva Tests That Can Be Administered Remotely

Genetic Testing Solution to Offer Easy and Convenient COVID-19 Testing for Providers Everywhere

Hygea Precision Medicine, a company focused on developing a precision medicine software system for healthcare providers and patients to effectively manage genetic testing, announced today that it has partnered with 1health.io, the leading Testing as a Service (TaaS) company. Hygea Precision Medicine’s partnership with 1health.io will allow it to deliver saliva-based COVID-19 tests to providers across the country.

1health.io empowers partners with the ability to offer convenient, non-invasive, and remote options for diagnostic testing. Partners can offer their patients, customers or employees diagnostic testing that eliminates inconvenient or even risky visits to testing centers while also eliminating long wait times for results. 1health.io’s platform allows partners, like Hygea Precision Medicine, to launch their private, secure, and scalable testing portal quickly, and to have tracking and reporting that is essential for supporting a large distributed team.

Hygea Precision Medicine provides a platform that promotes communication between a patient and their healthcare provider to optimize the patient’s treatment plan. The Hygea solution is a HIPAA compliant web-based software platform that connects providers, patients, and CLIA labs.

“When COVID-19 hit, we realized we could step in to deliver even more than genetic tests to providers,” said Devina Do, COO and Co-Founder of Hygea Precision Medicine. “Our intuitive software is trusted by physicians everywhere to assist in selecting, ordering, and assessing the most relevant genetic tests from laboratories. Now, with the help of 1health.io we are leveraging our seamless processes to deliver convenient at-home COVID-19 testing in order to fight this pandemic.”

1health.io provides testing as a service, enabling partners to easily deploy, manage, and personalize testing at scale. The company pioneered the concept and are the first in the field of DNA testing with a simple self administered COVID-19 saliva test that was authorized by the FDA under EUA earlier this year.

“We aim to make testing easy and accessible for everyone, and have developed the first technology infrastructure that turns testing into a service allowing our partners to launch testing in days all across the country,” said Mehdi Maghsoodnia, CEO of 1health.io. “Hygea Precision Medicine has fantastic infrastructure for providers, and their expertise in the field of genetic testing makes this partnership an evergreen one. For the time being, we are excited to help them provide their customers with an easy and convenient COVID-19 test option to help contain this pandemic.”

The tests can be taken from anywhere – at home, at work, in a hotel, or on-the-go. Saliva is collected in a tube, sealed with reagents, and shipped to a qualified lab in a secure envelope. Test results are delivered digitally to the person within 48 hours of the lab receiving the sample, and can be viewed on the secure patient dashboard on the 1health.io online platform.

About 1health.io

1health.io is the pioneer in enabling testing as a service, making diagnostic testing easy and accessible for everyone. Its platform powers engaging health applications for telehealth companies,

Read more

Shore Capital Partners Announces Founding of Southern Sports Medicine Partners

Strategic Partnership with Jaffe Sports Medicine Includes Four Locations in West Florida

Shore Capital Partners (“Shore”), a private equity firm, is pleased to announce it has founded Southern Sports Medicine Partners (“SSMP”), through the completion of a strategic partnership with Jaffe Sports Medicine (“JSM”). SSMP provides interventional pain management practices with administrative support, so physicians can focus on delivering the highest quality of patient care.

JSM, led by founder Dr. Peter Jaffe, provides patient-centric care at four locations in the Naples, FL area. Mike Cooper, a founding partner of Shore, commented, “We are thrilled to partner with Dr. Jaffe. He is one of the most respected and well-known physicians in West Florida. Having built a world-class practice, Dr. Jaffe shares our vision to deliver clinical excellence at greater scale.”

Dr. Jaffe said, “I partnered with Shore for their track record of transformational growth in healthcare and a shared belief in what it will take to be the leading interventional pain management platform in the Southeast. As healthcare continues to become more retail and consumer-oriented, the time is ideal to embrace growth, patient experience, and best in class programs and options for physicians in all stages of their careers. Southern Sports Medicine Partners is off to a great start and I have high aspirations for what we can achieve.”

SSMP will grow its platform across the region by investing in people and processes to support the operations, finance, accounting, marketing, human resources, and IT functions at affiliated practices, thereby allowing physicians to focus on clinical excellence and serving their communities. SSMP will pursue affiliations with independent interventional pain management practices to build a network of top clinicians in a physician-led culture.

“We are building a leader of scale in pain management and sports medicine, starting with Dr. Jaffe and his team,” said Mr. Cooper. “We are well-positioned to support the continued transition to consumer-directed healthcare, while maintaining the physician’s role and clinical expertise as the most critical aspect of treatment. Additionally, Shore has helped to bring together an exceptional board of directors consisting of industry thought leaders and physicians alike to guide our strategy and growth plan.”

SSMP represents the third platform investment out of Shore Capital Partners Fund III, L.P., a $293 million investment vehicle raised in April 2019.

To learn more about Jaffe Sports Medicine, please visit www.jaffesportsmedicine.com.

About Shore Capital

Shore Capital Partners is a Chicago-based private equity firm focused on microcap Healthcare and Food and Beverage investments. Shore supports management partners with capital, business development expertise, and industry knowledge to accelerate growth, fund acquisitions, and generate value to shareholders. Shore targets investments in proven, successful private companies with superior management teams, stable cash flow, and significant growth potential, including organic and growth through industry consolidation. Shore has $1.1 billion of equity capital under management through various investment vehicles. For more information on Shore, please visit www.shorecp.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20201102005029/en/

Contacts

Adam Werder
Shore Capital
(312) 348-7580
https://www.linkedin.com/company/shore-capital-partners/

Source Article

Read more

Strive Health Partners with Nearly 200 Nephrology Providers Across Multiple States to Implement Innovative Medicare Kidney Care Program

Strive Health, a national innovator in value-based kidney care, today announced that it has partnered with nearly 200 physicians and advanced practitioners from 20 nephrology groups across several states to participate in Medicare’s Comprehensive Kidney Care Contracting options of the Kidney Care Choices model (CKCC).

CKCC is a new Center for Medicare and Medicaid Innovation (CMMI) payment innovation model that incentivizes healthcare providers to manage the care of Medicare beneficiaries with chronic kidney disease (CKD) stages 4 and 5 and end stage renal disease (ESRD). Unlike prior value-based kidney care models, CKCC addresses both CKD and ESRD beneficiaries and aligns patients based on nephrology care, not dialysis treatments. The implementation period for the program started on October 15, 2020 and the official launch of the performance period is on April 1, 2021.

“New payment models like CKCC are putting nephrologists at the center and creating meaningful opportunities to transform care for our patients,” said Gary Singer, MD, a nephrologist who leads Midwest Nephrology Associates in St. Louis, MO. “We looked for a partner whose incentives align with our goal of delaying the progression of kidney disease, and whose model blends technological innovation with high-touch care. We believe Strive is well-positioned to support us in CKCC and beyond.”

Strive Health provides technology, high-touch care teams, and management expertise that empower nephrologists to participate and succeed in new value-based kidney care models. Physicians partnering with Strive gain access to advanced tools and resources that improve care delivery, such as sophisticated data science models that predict CKD disease progression with greater than 95% accuracy. Physicians also participate in performance-based incentive programs that reward high-quality and low-cost patient outcomes.

“Our company is the market leader in transformative, value-based kidney care. The new CMMI models take an exciting step in the right direction and create unprecedented opportunities for nephrologists to innovate and be rewarded for high-quality, long-term care goals over individual treatments,” said Chris Riopelle, CEO and co-founder of Strive Health.

Through partnerships with nephrologists and direct care arrangements, Strive manages thousands of complex CKD and ESRD patients in five states today and will be managing, or supporting the management of, more than 30,000 patients in 12 states by early 2021. The company is actively launching new value-based kidney care arrangements with commercial payors, health systems, and medical groups – most recently announced include Humana and Conviva Health – and engaging local nephrologists as central care providers within these models. Future growth plans include new application opportunities for CKCC and additional government programs.

About Strive Health

Strive Health is a national innovator in value-based kidney care and partner of choice for leading healthcare payors and providers. Through a unique combination of high-touch care teams, advanced technology, seamless integration with local providers, and next-generation dialysis services, Strive deploys an integrated care delivery system that supports the entire patient journey from chronic kidney disease (CKD) to end stage renal disease (ESRD). Strive partners with commercial and Medicare Advantage payors, Medicare, health systems, and physicians through

Read more

Northwestern Medicine Partners with Caption Health to Introduce New Artificially Intelligent Ultrasound Systems into Clinical Practice

Northwestern Medicine Partners with Caption Health to Introduce New Artificially Intelligent Ultrasound Systems into Clinical Practice

PR Newswire

CHICAGO, Oct. 28, 2020

Northwestern Memorial Hospital First in Country to Adopt Caption AI in Multiple Clinical Settings

CHICAGO, Oct. 28, 2020 /PRNewswire/ — Northwestern Memorial Hospital is the first hospital in the United States to purchase Caption Health’s artificial intelligence (AI) technology for ultrasound, Caption AI. The FDA cleared, AI-guided ultrasound system enables healthcare providers to acquire and interpret quality ultrasound images of the human heart, increasing access to timely and accurate cardiac assessments at the point of care.

Performing an ultrasound exam is a complex skill that takes years to master. Caption AI enables clinicians—including those without prior ultrasound experience—to quickly and accurately perform diagnostic-quality ultrasound exams by providing expert turn-by-turn guidance, automated quality assessment and intelligent interpretation capabilities. The systems are currently in the hospital’s emergency department, medical intensive care unit, cardio-oncology clinic and in use by the hospital medicine group.

“Through our partnership with Caption Health, we are looking to democratize the echocardiogram, a stalwart tool in the diagnosis and treatment of heart disease,” said Patrick McCarthy, MD, chief of cardiac surgery and executive director of the Northwestern Medicine Bluhm Cardiovascular Institute, a group involved in the early development of the technology. “Our ultimate goal is to improve cardiovascular health wherever we need to, and Caption AI is increasing access throughout the hospital to quality diagnostic images.”

Caption AI emulates the expertise of a sonographer by providing real-time guidance on how to position and manipulate the transducer, or ultrasound wand, on a patient’s body. The software shows clinicians in real time how close they are to acquiring a quality ultrasound image, and automatically records the image when it reaches the diagnostic-quality threshold. Caption AI also automatically calculates ejection fraction, or the percentage of blood leaving the heart when it contracts, which is the most widely used measurement to assess cardiac function.

“Northwestern Medicine has been a tremendous partner in helping us develop and validate Caption AI. We are thrilled that they are bringing Caption AI into key clinical settings as our first customer,” said Charles Cadieu, chief executive officer and co-founder of Caption Health. “The clinical, economic and operational advantages of using AI-guided ultrasound are clear. Most important, this solution increases access to a safe and effective diagnostic tool that can be life-saving for patients.”

Point-of-care ultrasound (POCUS) has a number of benefits. Increased usage of POCUS contributes to more timely and accurate diagnoses, more accurate monitoring and has been shown to lead to changes in patient management in 47% of cases for critically ill patients. POCUS also allows patients to avoid additional visits to receive imaging, as well as providing real-time results that can be recorded into a patient’s electronic medical record.

“I think the most exciting part is that Caption AI allows our intensive care unit (ICU) providers to do a point-of-care, real-time ultrasound for a sick patient,” said James “Mac”

Read more

VIDA Fitness Partners with the National Academy of Sports Medicine to Offer 20 Scholarships for Black Students Seeking Careers as Personal Trainers

WASHINGTON–(BUSINESS WIRE)–Oct 26, 2020–

VIDA Fitness is launching the Personal Training & Scholarship Mentorship Program in partnership with National Academy of Sports Medicine (NASM). The purpose of the program is to create more opportunities for Black aspiring personal trainers to have access to the certification program, textbooks, and mentorship necessary to launch a successful career in Washington, DC, Maryland, and Virginia.

“We want to bring more diversity into the fitness industry,” said David von Storch, President and Founder of VIDA Fitness. “This program will be a launchpad for individuals who are looking for ways to start successful careers. It will also help us meet hardworking, innovative Black trainers who may become future team members in the fitness industry.”

VIDA encourages Black students, returning citizens, fitness freelancers, and anyone who has demonstrated dedication, experience, and interest in pursuing a career in health and fitness to apply.

VIDA has appointed a Diversity & Inclusion Board that will review and interview the applications on a rolling basis. Over the next 6 – 12 months, twenty scholarship recipients will enter NASM’s Personal Training program, which is the fitness industry’s most respected certification. Upon successful completion of the NASM program and the certification exam, graduates will be invited to VIDA for a personal training mentorship.

“Our community of fitness professionals is strengthened by its diversity and its ongoing commitment to continuing education,” said Laurie McCartney, President of NASM. “We are proud to partner with VIDA Fitness on this very important initiative that will truly transform lives.”

VIDA Fitness will review applications on a monthly basis. For details about eligibility requirements and the application process, https://vidafitness.com/scholarship.

About VIDA Fitness: With 6 uniquely designed and thoughtfully laid out locations in downtown Washington, DC and Arlington, VA, VIDA Fitness provides industry-leading facilities and programming, all powered by the best fitness professionals to support you in achieving your goals, and creating a community where people of shared values can make meaningful personal connections.

About NASM: Now in its 33rd year, the National Academy of Sports Medicine (NASM) has remained the international standard in fitness education due to the high quality of fitness professionals they produce and the scientific rigor of their programs. NASM offers a best in class Certified Personal Training program along with major specializations in Nutrition Coaching (CNC), Sports Performance (PES), and Corrective Exercise (CES).

View source version on businesswire.com:https://www.businesswire.com/news/home/20201026005138/en/

CONTACT: Alyson Campbell

Heart & Soul PR for NASM

646.895.2841

KEYWORD: UNITED STATES NORTH AMERICA MARYLAND VIRGINIA DISTRICT OF COLUMBIA

INDUSTRY KEYWORD: EDUCATION HEALTH SPORTS OTHER SPORTS FITNESS & NUTRITION CONTINUING TRAINING

SOURCE: National Academy of Sports Medicine

Copyright Business Wire 2020.

PUB: 10/26/2020 09:00 AM/DISC: 10/26/2020 09:02 AM

http://www.businesswire.com/news/home/20201026005138/en

Source Article

Read more

Aridis Pharmaceuticals to Present at the ROTH Capital Partners 2020 MedTech Innovation Forum on a COVID-19 Panel

SAN JOSE, Calif., Oct. 27, 2020 /PRNewswire/ — Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies to treat life-threatening infections, today announced the Company will present at the ROTH Capital Partners 2020 MedTech Innovation Forum on Wednesday, October 28, 2020. Dr. Hasan Jafri, Chief Medical Officer of Aridis Pharmaceuticals, will be a speaker on a panel entitled “Direct Antivirals and Other Agents Against SARS-CoV2 Virus.”

Panel: Direct Antivirals and Other Agents Against SARS-CoV2 Virus
Date: Wednesday, October 28, 2020
Time: 10:30AM-11:50AM ET

Dr. Jafri will present a summary of the Company’s recently published preclinical data of its COVID-19 inhaled mAb (AR-711). He will address the preclinical performance of AR-711, the advantages of direct lung delivery using nebulized aerosols, and the COVID-19 clinical program.

About AR-711

AR-711 is a fully human immunoglobulin 1, or IgG1, monoclonal antibody discovered from screening the antibody secreting B-cells of convalescent COVID-19 patients. AR-711 exhibits high affinity for SARS-CoV-2 spike protein, approximately 10-fold or higher than mAb candidates currently in late stage clinical testing. AR-711 was previously shown to be effective in prophylactic as well as therapeutic treatment modes in a SARS-CoV-2 viral challenge study. AR-711 is currently being developed as an inhaled, self-administered treatment for non-hospitalized patients suffering from mild to moderate COVID-19. AR-711 is also one the two mAbs in the company’s AR-701 mAb cocktail, which is a separate program being developed as an intravenous treatment of moderate to severe, hospitalized COVID-19 patients.

About Aridis Pharmaceuticals, Inc.

Aridis Pharmaceuticals, Inc. discovers and develops anti-infectives to be used as add-on treatments to standard-of-care antibiotics. The Company is utilizing its proprietary ʎPEXTM and MabIgX® technology platforms to rapidly identify rare, potent antibody-producing B-cells from patients who have successfully overcome an infection, and to rapidly manufacture monoclonal antibody (mAbs) for therapeutic treatment of critical infections. These mAbs are already of human origin and functionally optimized for high potency by the donor’s immune system; hence, they technically do not require genetic engineering or further optimization to achieve full functionality.

The Company has generated multiple clinical stage mAbs targeting bacteria that cause life-threatening infections such as ventilator associated pneumonia (VAP) and hospital acquired pneumonia (HAP), in addition to preclinical stage antiviral mAbs. The use of mAbs as anti-infective treatments represents an innovative therapeutic approach that harnesses the human immune system to fight infections and is designed to overcome the deficiencies associated with the current standard of care which is broad spectrum antibiotics. Such deficiencies include, but are not limited to, increasing drug resistance, short duration of efficacy, disruption of the normal flora of the human microbiome and lack of differentiation among current treatments. The mAb portfolio is complemented by a non-antibiotic novel mechanism small molecule anti-infective candidate being developed to treat lung infections in cystic fibrosis patients. The Company’s pipeline is highlighted below:

Aridis’ Pipeline

AR-301 (VAP). AR-301 is a fully human IgG1 mAb currently in Phase 3 clinical development targeting gram-positive 

Read more

VIDA Fitness Partners with the National Academy of Sports Medicine to Offer 20 Scholarships for Black Students Seeking Careers as Personal Trainers – Press Release

WASHINGTON–(Business Wire)–VIDA Fitness is launching the Personal Training & Scholarship Mentorship Program in partnership with National Academy of Sports Medicine (NASM). The purpose of the program is to create more opportunities for Black aspiring personal trainers to have access to the certification program, textbooks, and mentorship necessary to launch a successful career in Washington, DC, Maryland, and Virginia.

“We want to bring more diversity into the fitness industry,” said David von Storch, President and Founder of VIDA Fitness. “This program will be a launchpad for individuals who are looking for ways to start successful careers. It will also help us meet hardworking, innovative Black trainers who may become future team members in the fitness industry.”

VIDA encourages Black students, returning citizens, fitness freelancers, and anyone who has demonstrated dedication, experience, and interest in pursuing a career in health and fitness to apply.

VIDA has appointed a Diversity & Inclusion Board that will review and interview the applications on a rolling basis. Over the next 6 – 12 months, twenty scholarship recipients will enter NASM’s Personal Training program, which is the fitness industry’s most respected certification. Upon successful completion of the NASM program and the certification exam, graduates will be invited to VIDA for a personal training mentorship.

“Our community of fitness professionals is strengthened by its diversity and its ongoing commitment to continuing education,” said Laurie McCartney, President of NASM. “We are proud to partner with VIDA Fitness on this very important initiative that will truly transform lives.”

VIDA Fitness will review applications on a monthly basis. For details about eligibility requirements and the application process, https://vidafitness.com/scholarship.

About VIDA Fitness: With 6 uniquely designed and thoughtfully laid out locations in downtown Washington, DC and Arlington, VA, VIDA Fitness provides industry-leading facilities and programming, all powered by the best fitness professionals to support you in achieving your goals, and creating a community where people of shared values can make meaningful personal connections.

About NASM: Now in its 33rd year, the National Academy of Sports Medicine (NASM) has remained the international standard in fitness education due to the high quality of fitness professionals they produce and the scientific rigor of their programs. NASM offers a best in class Certified Personal Training program along with major specializations in Nutrition Coaching (CNC), Sports Performance (PES), and Corrective Exercise (CES).

Alyson Campbell

Heart & Soul PR for NASM

646.895.2841

// Load the SDK Asynchronously (function(d){ var js, id = 'facebook-jssdk', ref = d.getElementsByTagName('script')[0]; if (d.getElementById(id)) {return;} js = d.createElement('script'); js.id = id; js.async = true; js.src = "http://connect.facebook.net/en_US/all.js"; ref.parentNode.insertBefore(js, ref); })(document); })();

Source Article

Read more

Britain partners with Oxford firm to assess coronavirus vaccine T cell responses

LONDON (Reuters) – Britain on Thursday said it would partner with an Oxford-based firm to provide testing for the T cell response of coronavirus vaccine candidates to try to assess their immune responses.

T cell immunity is thought to be essential to protection against infection from the SARS-COV-2 coronavirus, and could provide longer term immunity than antibodies.

The UK Vaccine Taskforce has chosen Oxford Immunotec to supply T cell testing for its assessment of different vaccine candidates.

“It is important to be able to assess the different vaccines head-to-head and the T cell response is part of our portfolio of accredited assays that we are employing for cross comparisons,” Kate Bingham, chair of the UK Vaccines Taskforce, said in a statement.

Britain has signed supply deals for six different coronavirus vaccine candidates, including those being made by AstraZeneca <AZN.L> and Pfizer <PFE.N> and BioNTech <22UAy.F>, seen as among the frontrunners in the race for a vaccine.

Oxford Immunotec said its techonology platform enabled the centralisation of fresh blood samples from different locations to measure the T cell response in a standardised way.

It said the platform, known as T-SPOT, was being used to identify the T cells made in response to the pathogen that causes tuberculosis.

(Reporting by Alistair Smout; editing by Barbara Lewis)

Source Article

Read more